Ezivac%25252525252525252525252525252525252520enema

# Ezivac Enema ## Overview Ezivac enema is a hypertonic phosphate solution used as a saline laxative. It works by osmotic pressure to draw fluid into the colon, promoting distension and stimulating peristalsis. It is intended for short-term use for constipation or bowel cleansing prior to procedures. ## Primary Indications * Relief of occasional constipation. * Bowel evacuation prior to proctoscopic, sigmoidoscopic, or radiologic examinations. ## Adult Dosing * **Standard Dose:** 118 mL (one ready-to-use unit) administered rectally as a single dose. * **Maximum Dose:** Do not exceed one unit per 24 hours. ## Pediatric Dosing * **Children 12 years and older:** Same as adult dosing (118 mL). * **Children 2 to 11 years:** 59 mL (partial unit or pediatric-specific product) as a single dose. * **Children under 2 years:** Contraindicated. * *Note: Always verify local hospital or institutional protocol, as pediatric dosing of hypertonic phosphate enemas carries significant risk of electrolyte disturbances.* ## Dose Adjustments * **Renal Impairment:** Use with extreme caution; avoid in patients with baseline renal insufficiency due to risk of hyperphosphatemia, hypocalcemia, and hypernatremia. * **Hepatic Impairment:** No specific adjustment necessary, but monitor fluid status. ## Contraindications * Known hypersensitivity to phosphates. * Megacolon (congenital or acquired). * GI obstruction, imperforate anus, or active inflammatory bowel disease. * Severe renal impairment. * Congestive heart failure or ascites (due to sodium loading). ## Adverse Effects * **Common:** Rectal irritation, abdominal pain, nausea. * **Serious:** Severe electrolyte imbalances (hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia), dehydration, EKG changes (QT prolongation secondary to hypocalcemia), and potential for rectal mucosal injury/perforation. ## Key Drug Interactions * **Diuretics:** Increased risk of electrolyte imbalances and dehydration. * **Calcium Channel Blockers/Medications that prolong QT:** Risk of additive QT prolongation if electrolyte shifts occur (specifically hypocalcemia/hypokalemia). * **Nephrotoxic agents:** Concurrent use increases risk of acute phosphate nephropathy. ## Monitoring * **Electrolytes:** Serum phosphate, calcium, sodium, and potassium in high-risk patients. * **Renal Function:** Serum creatinine if repeating or in susceptible populations. * **Hydration Status:** Monitor for signs of excessive fluid loss. ## Clinical Pearls * **Administration:** Ensure the patient is in the left lateral decubitus position (Sims’ position) for administration. Do not force the tip, as this can cause mucosal trauma or perforation. * **Risk Profile:** Hypertonic phosphate enemas can cause rapid, severe shifts in serum electrolytes; deaths have been reported in children and elderly patients due to electrolyte toxicity. * **Duration:** If no bowel movement occurs after administration, do not repeat; contact a healthcare provider as this may indicate a fecal impaction or obstruction. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines vary by institution and region. Always verify specific dosing and contraindications against current FDA-approved labeling, local institutional protocols, and current serum electrolyte values before prescribing or administering Ezivac.